Antioxidant and Neuroprotective Potential of Natural Compounds: Focus on Alzheimer’s Disease

Dear Colleagues,

Alzheimer’s disease (AD) is an irreversible and progressive neurodegenerative disease. Dementia is the leading cause of AD that affects about over 30 million people worldwide. According to the world Alzheimer report 2018, new case of dementia develops in every three seconds around the world. AD is a major disease has no effective ways to cure, reverse and slow down of disease progression once symptoms start. Many researchers are used multi-target strategies for the treatment of AD such as β-amyloid peptide aggregation inhibitors, γ and β-secretase inhibitors & modulators, anti-amyloid immunotherapy, tau hyperphosphorylation inhibitors (e.g. JNK3, CDK5, GSK3β & Fyn kinase), tau aggregation inhibitors, microtubules stabilization, anti-tau immunotherapy, AChE inhibitors, 5-HT6 antagonism, anti-diabetic/metabolic regulation therapies and Cdk5 inhibitors but these approaches have a limited success to cure the AD. Beside the use of above medicinal treatment, Natural compounds are also contributed to several distinctive treatments modalities for the treatment of the AD without side effect. So this special issue will specially focus on to natural compounds for the treatment of Alzheimer’s disease.

We invite researchers to contribute original research and review articles that will help to elucidate the therapeutic potential for Alzheimer’s disease. We encourage the submission of all the studies dealing with the use of natural compound describing the role of respective herbs for neuroprotective and ant-oxidative properties in Alzheimer’s disease.

Dr. Sandeep Singh
Dr. Burkhard Poeggeler
Dr. Mahendra P. Singh
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.